J S Walsh
Overview
Explore the profile of J S Walsh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
572
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dowling L, McCloskey E, Cuthbertson D, Walsh J
J Frailty Aging
. 2023 Jan;
12(1):37-42.
PMID: 36629082
Background: Obesity and low muscle strength (dynapenia) are independently associated with greater falls risk. It remains unclear whether dynapenia and obesity have an additive effect on falls risk, greater than...
2.
Vilaca T, Evans A, Gossiel F, Paggiosi M, Eastell R, Walsh J
Eur J Endocrinol
. 2022 Sep;
187(6):743-750.
PMID: 36173650
Context: Obese (OB) adults (BMI ≥ 30) have a higher bone mineral density (BMD) and more favourable bone microarchitecture than normal-weight (NW) adults (BMI 18.5-24.9). Objective: The objective of this...
3.
Orlando G, Bubbear J, Clarke S, Keen R, Roy M, Anilkumar A, et al.
Osteoporos Int
. 2022 Feb;
33(7):1485-1491.
PMID: 35122145
Introduction: There is a dearth of literature on physical function and physical activity in adults with X-linked hypophosphatemia (XLH). We described muscle strength and power, functional capacity, mobility and physical...
4.
Gossiel F, Ugur A, Peel N, Walsh J, Eastell R
Osteoporos Int
. 2022 Feb;
33(6):1357-1363.
PMID: 35102444
Introduction: Bone turnover markers (BTMs) can be used to monitor response to osteoporosis treatment. However, some are affected by food intake and are not suitable to measure in a clinical...
5.
Schini M, Peel N, Toronjo-Urquiza L, Thomas E, Salam S, Khwaja A, et al.
Osteoporos Int
. 2021 Oct;
33(3):737-744.
PMID: 34654939
Introduction: Zoledronate is widely used for the treatment of osteoporosis. A potential side effect is acute kidney injury (AKI). Advice from the UK Medicines and Healthcare products Regulatory Agency (MHRA)...
6.
Du J, Hartley C, Brooke-Wavell K, Paggiosi M, Walsh J, Li S, et al.
Osteoporos Int
. 2020 Nov;
32(5):907-919.
PMID: 33196852
Introduction: The localisation of bone remodelling and microarchitectural adaptation to exercise loading has not been demonstrated previously in vivo in humans. The aim of this study is to assess the...
7.
Paggiosi M, Debono M, Walsh J, Peel N, Eastell R
Osteoporos Int
. 2020 Jan;
31(4):667-675.
PMID: 31993717
Introduction: We evaluated the ability of lumbar spine bone mineral apparent density (BMAD), trabecular bone score (TBS) and volumetric bone mineral density (vBMD) to discriminate between postmenopausal women with low...
8.
Naylor K, McCloskey E, Jacques R, Peel N, Paggiosi M, Gossiel F, et al.
Osteoporos Int
. 2019 Jan;
30(4):917-922.
PMID: 30613868
Introduction: Measurement of bone turnover markers (BTMs) may be useful to monitor offset of treatment with bisphosphonates (BP) in osteoporosis. We assessed the effect of withdrawal of BP treatment by...
9.
Naylor K, Bradburn M, Paggiosi M, Gossiel F, Peel N, McCloskey E, et al.
Osteoporos Int
. 2018 Mar;
29(6):1407-1417.
PMID: 29525970
Introduction: Bisphosphonates (BPs) continue to suppress bone turnover markers (BTMs) after treatment has stopped, leading to the suggestion that a pause in treatment could be considered for low-risk patients. Indirect...
10.
Paggiosi M, Yang L, Blackwell D, Walsh J, McCloskey E, Peel N, et al.
Osteoporos Int
. 2018 Mar;
29(6):1367-1378.
PMID: 29520607
Introduction: Teriparatide stimulates bone formation and resorption and therefore can cause bone gain and loss. We simultaneously characterised the central and peripheral skeleton using imaging techniques to better understand the...